These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2988459)

  • 21. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
    Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK
    J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
    Bruntsch U; de Mulder PH; ten Bokkel Huinink WW; Clavel M; Drozd A; Kaye SB; Renard J; van Glabbeke M
    J Biol Response Mod; 1990 Jun; 9(3):335-8. PubMed ID: 2116500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
    Trump DL; Elson PJ; Borden EC; Harris JE; Tuttle RL; Whisnant JK; Oken MM; Carignan JR; Ruckdeschel JC; Davis TE
    Cancer Treat Rep; 1987 Feb; 71(2):165-9. PubMed ID: 3802113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial.
    Otto U; Conrad S; Schneider AW; Klosterhalfen H
    Arzneimittelforschung; 1988 Nov; 38(11):1658-60. PubMed ID: 3145743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
    Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
    J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1 study of recombinant interferon-gamma given intravenously by portable mini-pump: a preliminary report.
    Sriskandan K; Garner P; Watkinson J; Gerlis L; Tee DE
    Int J Clin Pharmacol Res; 1984; 4(6):469-74. PubMed ID: 6241930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Taylor W; Laszlo J
    Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
    Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
    Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneously administered recombinant interferon-gamma in humans: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages, blood neutrophils, and monocytes.
    Halme M; Maasilta P; Repo H; Leirisalo-Repo M; Taskinen E; Mattson K; Cantell K
    J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):283-91. PubMed ID: 8061901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
    Sarna G; Figlin R; Callaghan M
    J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
    Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
    Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in skin malignant tumors].
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):936-42. PubMed ID: 2985007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma.
    Cancer; 1987 Sep; 60(5):929-33. PubMed ID: 3111677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.
    Von Hoff DD; Fleming TR; Macdonald JS; Goodman PJ; Van Damme J; Brown TD; O'Rourke T; Feun LG; Keppen MD
    J Biol Response Mod; 1990 Dec; 9(6):584-7. PubMed ID: 2127424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I clinical trial of recombinant DNA gamma interferon.
    Brown TD; Koeller J; Beougher K; Golando J; Bonnem EM; Spiegel RJ; Von Hoff DD
    J Clin Oncol; 1987 May; 5(5):790-8. PubMed ID: 3106584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American cancer society Phase I trial of naturally produced beta-interferon.
    Hawkins MJ; Krown SE; Borden EC; Krim M; Real FX; Edwards BS; Anderson SA; Cunningham-Rundles S; Oettgen HF
    Cancer Res; 1984 Dec; 44(12 Pt 1):5934-8. PubMed ID: 6498851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.